PiSCATIN study reaches full recruitment milestone
PiSCATIN study reaches full recruitment milestone
Professor Annika Bergquist
The PiSCATIN clinical trial, which is evaluating the use of simvastatin in patients with primary sclerosing cholangitis (PSC), has successfully reached its recruitment target. A total of 570 participants have been enrolled in the study, and recruitment officially closed on 15 April 2025.
What is the current status of the study?
The study is now in the treatment and monitoring phase. A new batch of study medication has been received, ensuring that all participants can continue their treatment according to the protocol. The study team is also conducting ongoing quality control of data from the first 25 participants who have already completed the study.
When will the results be available?
While the study is progressing well, clinical trials require significant time to ensure findings are robust and accurate. The timeline for the interim analysis has been updated and is currently scheduled for March 2027. This analysis will provide vital insights into the progress and safety of the treatment.
Why is this research important?
PSC is a rare, immune-mediated liver disease that currently has no proven medical treatment to stop or slow its progression. By investing in trials like PiSCATIN, PSC Support aims to unlock the understanding of disease processes and establish evidence-based treatments that can improve health outcomes for the PSC community.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Building Partnerships: We contributed a comprehensive chapter to a new medical textbook for nurses and allied health professionals, ensuring that the patient perspective is integrated into clinical education.
Building Partnerships: We participated in a planning meeting for the update of national clinical guidelines for PSC.
Building Partnerships: We prepared strategic questions for an upcoming international forum titled “Putting Patients First: From Research to Treatment.”
Organisational Excellence: We updated our web details to make it less likely information from us sent by email ends up in your spam folders.
Progressing Research: We are collaborating with European partners to develop a simplified research registry for pregnancy outcomes, building the evidence base needed to improve medical guidance for women with PSC.
Progressing Research: We completed a formal submission to the Scottish Medicines Consortium to advocate for the value of a potential new treatment for PSC patients.
Progressing Research: We reviewed the participant information for a new academic clinical trial to ensure it is clear and accessible for patients.